Pharmacokinetics and Safety of Tegoprazan in Hepatic Impairment

Phase 1, open-label trial of tegoprazan in gastroesophageal reflux disease (GERD) and peptic ulcer disease (PUD) (4 arms), sponsored by HK inno.N Corporation. Primary endpoints: Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration up to 48 hours and Maximum Plasma Concentration up to 48 hours. Status: unknown.